logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 9 of 9 Items
Showing 1 - 9 of 9 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Ismail N, Omar SV, Moultrie H, Bhyat Z, Conradie F,  et al.
2021-11-12 • Lancet Infectious Diseases
2021-11-12 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Journal Article
|
Research

Early mortality during rifampicin-resistant TB treatment

Mohr-Holland E, Daniels J, Reuter A, Rodriguez CA, Mitnick CD,  et al.
2022-02-01 • International Journal of Tuberculosis and Lung Disease
2022-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality ...
Journal Article
|
Research

Implementing a substance-use screening and intervention program for people living with rifampicin-resistant tuberculosis: pragmatic experience from Khayelitsha, South Africa

Reuter A, Beko B, Memani B, Furin J, Daniels J,  et al.
2022-01-31 • Tropical Medicine and Infectious Disease
2022-01-31 • Tropical Medicine and Infectious Disease
Substance use (SU) is associated with poor rifampicin-resistant tuberculosis (RR-TB) treatment outcomes. In 2017, a SBIRT (SU screening-brief intervention-referral to treatment) was inte...
Journal Article
|
Research

Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?

Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...
Journal Article
|
Research

"Life continues": Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa

Mohr E, Snyman L, Mbakaz Z, Caldwell J, De Azevedo V,  et al.
2018-09-14 • PLOS One
2018-09-14 • PLOS One
BACKGROUND
Self-administered treatment (SAT), a differentiated model of care for rifampicin-resistant tuberculosis (RR-TB), might address adherence challenges faced by patients and h...
Journal Article
|
Research

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa

Mohr-Holland E, Reuter A, Furin J, Garcia-Prats AJ, De Azevedo V,  et al.
2020-03-01 • eClinicalMedicine
2020-03-01 • eClinicalMedicine
BACKGROUND
Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10-19...
Journal Article
|
Letter

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?

Ndjeka N, Conradie F, Meintjes GA, Reuter A, Hughes J,  et al.
2020-07-23 • European Respiratory Journal
2020-07-23 • European Respiratory Journal
Rapid adoption of new diagnostic tools, parallel process of research and implementation, decentralisation of services, the use of personal protective equipment, as well as strong partner...
Journal Article
|
Research

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa

Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G,  et al.
2018-05-03 • European Respiratory Journal
2018-05-03 • European Respiratory Journal
Experience with delamanid (Dlm) is limited, particularly among HIV-positive individuals. We describe early efficacy and safety data from a programmatic setting in South Africa. This was ...
Journal Article
|
Letter

Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa"

Mohr-Holland E, Reuter A, Hughes J, Daniels J, Beko B,  et al.
2020-07-01 • European Respiratory Journal
2020-07-01 • European Respiratory Journal